Intercept Pharmaceuticals sold by Genextra S.P.A.: $50.38m-May 13
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company's product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions. The Company's product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). In addition to OCA, it is developing other bile acid analog compounds targeting FXR and a second dedicated bile acid receptor called TGR5, which is a target of interest for the treatment of type 2 diabetes and other gastrointestinal indications. The Company is also developing other products INT-767 for the treatment of fibrosis and INT-777 for the treatment of type 2 diabetes. Number of employees : 583 people.
https://www.marketscreener.com/INTERCEPT-PHARMACEUTICALS-11718561/company/
Founder and Executive Chairman-Genextra S.P.A-Francesco Micheli
Francesco has served as chairman of the board since Genextra’s inception in 2003. Previously, a key player in the financial sector (Gruppo Montedison, IMI, Morgan Grenfell, ING e Sviluppo Finanziaria), he participated to the start-up and launch of successful businesses such as e.Biscom-Fastweb in 2000. Francesco is a member of the Board of Directors of a number of companies including philanthropic institutes such as Fondazione Teatro alla Scala, FAI, Associazione Orchestra Filarmonica della Scala, MilanoMusica, Fondazione Amici della Scala, Fondazione Teatro Parenti, Vidas, Istituto Europeo di Neuroscienze, Fondazione Basso, Fondazione Mazzotta. Through the Musical Foundation of Umberto Micheli, and together with Maurizio Pollini, Francesco launched Milan’s world renowned International Piano Competition Umberto Micheli. He is also President of the Association for the International Milan Music Festival that successfully promoted the renowned music festival “MITO”. Francesco also served on the consulting committee for Expo2015.
http://www.genextra.it/team/
Mario Draghi's daughter is Director Biochemistry Genextra S.p.A, Italy
Mario Draghi served as President of the European Central Bank between 2011 and 2019. Before that, he served as the Chairman of the Financial Stability Board from 2009 to 2011 and Governor of the Bank of Italy from 2005 to 2011-previously worked at Goldman Sachs from 2002 until 2005
Federica joined Genextra in May 2006 and since then has been involved in a number of activities ranging from evaluation of new investing opportunities to partnering, licensing as well as strategic development of Genextra's subsidiary companies. Federica is also Chief Operating Officer of Congenia s.r.l. and member of the Board of Directors of Erydel S.p.A. Before joining Genextra, Federica acquired experience in the technology transfer area at Windham Venture Partners, a NYC based life sciences technology commercialization firm, and before that with Science and Technology ventures, Columbia University's technology transfer office. Prior to that she was a postdoc at the MRC in Cambridge (UK.) and has been published in several journals. Federica holds an MBA from Columbia University and a PhD in Biochemistry from La Sapienza, University of Rome."
https://biography.omicsonline.org/italy/genextra-spa/dr-federica-draghi-phd-mba-153937
https://www.finviz.com/insidertrading.ashx?oc=1559515&tc=7&b=2